Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5717954 | 0.92 | KCNQ3 (0.35) | KCNQ3KCNQ2ITGB3ITGA2BOPRK1 | |
| SCHEMBL5718138 | 0.82 | KCNQ3 (0.46) | KCNQ3KCNQ2F2HTTKDM1A | |
| SCHEMBL5717956 | 0.81 | PRCP (0.36) | KCNQ3KCNQ2F2CASP3 | |
| SCHEMBL5718148 | 0.75 | KCNQ3 (0.38) | KCNQ3KCNQ2OPRK1 | |
| SCHEMBL6801993 | 0.74 | KCNQ3 (0.54) | KCNQ3KCNQ2F2TSHRKDM1A | |
| SCHEMBL5838749 | 0.74 | KCNQ3 (0.41) | KCNQ3KCNQ2F2HTT | |
| SCHEMBL5718093 | 0.73 | KCNQ3 (0.53) | KCNQ3KCNQ2F2HTTMAOA | |
| SCHEMBL6391978 | 0.69 | SMN1; SMN2 (0.50) | F2CYP3A4TSHRHTT | |
| SCHEMBL6389440 | 0.69 | SMN1; SMN2 (0.50) | F2CYP3A4TSHRHTT | |
| SCHEMBL5839244 | 0.69 | KCNQ3 (0.47) | KCNQ3KCNQ2F2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1318977-B1 | SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-12-06 | — | — | EP | disclosed |
| US-7074780-B2 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20040122004-A1 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
| US-6649616-B2 | For therapy and prophylaxis of cardiovascular disorders caused by ischaemia | BAYER AKTIENGESELLSCHAFT (DE) | 2003-11-18 | — | — | US | disclosed |
| US-20030008881-A1 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008881-A1 | Substituted phenylcyclohexanecarboxamides and their use | TNNI3, PAH, P4HA1 | KCNQ3 1604/4885KCNQ2 1282/4885F2 995/4885 |
| US-20040122004-A1 | Substituted phenylcyclohexanecarboxamides and their use | TNNI3, PAH, P4HA1 | KCNQ3 1604/4885KCNQ2 1282/4885F2 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.